{"entity": "publication", "iuid": "087975263b344b6a9a5a4b345306fd9c", "timestamp": "2026-09-01T08:31:54.201Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/087975263b344b6a9a5a4b345306fd9c.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/087975263b344b6a9a5a4b345306fd9c"}}, "title": "Proinflammatory allogeneic dendritic cells enhance the therapeutic efficacy of systemic anti-4-1BB treatment.", "authors": [{"family": "Ali", "given": "Arwa", "initials": "A"}, {"family": "Gao", "given": "Menghan", "initials": "M"}, {"family": "Iskantar", "given": "Alexandros", "initials": "A"}, {"family": "Wang", "given": "Hai", "initials": "H"}, {"family": "Karlsson-Parra", "given": "Alex", "initials": "A"}, {"family": "Yu", "given": "Di", "initials": "D"}, {"family": "Jin", "given": "Chuan", "initials": "C"}], "type": "journal article", "published": "2023-08-15", "journal": {"title": "Front Immunol", "issn": "1664-3224", "volume": "14", "pages": "1146413", "issn-l": "1664-3224"}, "abstract": "As an immune adjuvant, proinflammatory allogeneic dendritic cells (AlloDCs) have demonstrated promising immune-priming effects in several preclinical and clinical studies. The effector cells, including NK cells and T cells are widely acknowledged as pivotal factors in the effectiveness of cancer immunotherapy due to their ability to selectively identify and eradicate malignant cells. 4-1BB, as a costimulatory receptor, plays a significant role in the stimulation of effector cell activation. This study evaluated the anti-tumor effects when combining intratumoral administration of the immune-adjuvant AlloDCs with systemic \u03b14-1BB treatment directly acting on effector cells. In both the CT-26 murine colon carcinoma model and B16 murine melanoma model, AlloDCs demonstrated a significant enhancement in the therapeutic efficacy of \u03b14-1BB antibody. This enhancement was observed through the delayed growth of tumors and prolonged survival. Analysis of the tumor microenvironment (TME) in the combined-treatment group revealed an immune-inflamed TME characterized by increased infiltration of activated endogenous DCs and IFN\u03b3+ CD8+ T cells, showing reduced signs of exhaustion. Furthermore, there was an augmented presence of tissue-resident memory (TRM) CD8+ T cells (CD103+CD49a+CD69+). The combination treatment also led to increased infiltration of CD39+CD103+ tumor-specific CD8+ T cells and neoantigen-specific T cells into the tumor. Additionally, the combined treatment resulted in a less immunosuppressive TME, indicated by decreased infiltration of myeloid-derived suppressor cells and Tregs. These findings suggest that the combination of intratumoral AlloDCs administration with systemic agonistic \u03b14-1BB treatment can generate a synergistic anti-tumor response, thereby warranting further investigation through clinical studies.", "doi": "10.3389/fimmu.2023.1146413", "pmid": "37654492", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10466132"}], "notes": [], "created": "2026-08-21T12:59:02.647Z", "modified": "2026-08-21T12:59:02.660Z"}